65,437 trials
Anorectal Disorder
Primary: Total Narcotic Use Postoperatively in Oral Morphine Equivalents — 8; 79 Oral morphine miligram equivalents
Lung Cancer
Primary: Motivation to Quit Smoking — 4.95; 3.30; 5.49; 4.52 units on a scale
Infection
Primary: Number of Participants Who Received at Least One Dose of Ceftazidime-Avibactam Classified According to Type of Usage as Monotherapy or Combination Therapy: FAS 72+…
Malignant Central Nervous System Neoplasm · Metastatic Malignant Neoplasm in the Central Nervous System
Primary: Number of Participants With Grade 2 or Higher Toxicities — 0; 0 Participants
Healthy
Primary: Change in Corticomotor Excitability With Active Stimulation on Bicep Muscle — 6.9 percentage of Mwave
Anesthesia
Primary: Slope of EEG Theta Band Power Over Fentanyl Effect Site Concentration (dB/ng/mL) — 0.55 dB / nano gram / mL
Healthy Volunteers
Primary: Part I: Area Under the Plasma Concentration-time Curve From Time Zero to Time of the Last Quantifiable Concentration (AUClast) of rhPTH (1-84) — 471.9; 603.1…
Pain, Postoperative · Ankle Fractures
Primary: Change in Post-operative Visual Analog Pain Scores (VAS) — 42; 52; 41; 50 0 to 100 score on a scale
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 24 — -0.13; -1.12; -1.12 Percentage of glycosylated hemoglobin — p=< 0.0001
Scleroderma, Systemic · Interstitial Lung Disease
Primary: Percent Predicted Forced Vital Capacity (FVC-%) — 2.24; 2.09 percent predicted — p=0.9326
Hyperlipidaemia
Primary: Percentage Change From Baseline on Serum LDL-C — -56.7; 5.6 percent change — p=<0.001
Pancreatic Cancer · Stereotactic Body Radiation Therapy
Primary: CTCAE Grade 3 or 4 Gastro-intestinal (GI) Toxicities or Death Within 90 Days From the Start of Therapy — 1; 0; 0; 0 Events
Psoriasis · Plaque Psoriasis
Primary: Plasma Concentration of ARQ-151 Cream 0.3% — 3.15; 1.68 ng/mL
Oral Lichen Planus · Mucous Membrane Pemphigoid · Pemphigus Vulgaris
Primary: Mean Change From Baseline in Oral Pain Scores on the Visual Analog Scale (VAS) at 4 Weeks — 6.3; 4.4 score on a scale
Lip Augmentation · Lip
Primary: Change in TLFS Score (Teoxane Lip Fullness Scale) Between Baseline and Week 12 After Last Treatment of RHA®3 Versus Control Device, as Assessed by the BLE — 1.0; 0.8…